Orega Biotech
OREGA Biotech is dedicated to transforming scientific insights in tumor immunology into innovative cancer immunotherapies. The company specializes in developing first-in-class monoclonal antibodies targeting novel immune checkpoints and regulators of antitumoral immunity. Their mission is to improve current cancer treatment strategies, response rates, and patient survival through early partnerships with biotech and pharma companies. Their most advanced program, a humanized CD39 antibody licensed to Innate Pharma/AstraZeneca, is in phase 2 clinical trials for non-small cell lung cancer.
Industries
Nr. of Employees
small (1-50)
Orega Biotech
Espace Européen, bâtiment G, 15 chemin du Saquin, 69130 Ecully, France
Patents
Nucleic acids encoding and methods of producing proteins comprising antibody chains
US-12202907-B2
View DetailsAntibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
US-11377503-B2
View Details
Nucleic acids encoding and methods of producing proteins comprising antibody chains
US-12202907-B2
View DetailsAntibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
US-11377503-B2
View DetailsProducts
Anti-CD39 monoclonal antibody (clinical-stage)
A humanized CD39-blocking monoclonal antibody that inhibits membrane and soluble CD39 to reduce adenosine production and favor peritumoral ATP accumulation; developed as an immunotherapy and evaluated in combination with PD-L1 blockade and chemotherapy.
Novel regulator-of-anti-PD1 antibody program (preclinical)
A preclinical antibody program targeting an undisclosed regulator of anti-PD1 response demonstrated to reverse resistance in syngeneic mouse models; lead humanized antibody licensed to a commercial partner for further development.
Anti-IL-17 neutralizing antibody program (preclinical)
Generation and characterization of neutralizing monoclonal antibodies against IL-17 family cytokines with in vivo proof-of-concept showing antitumor activity through modulation of the tumor microenvironment.
Anti-CD39 monoclonal antibody (clinical-stage)
A humanized CD39-blocking monoclonal antibody that inhibits membrane and soluble CD39 to reduce adenosine production and favor peritumoral ATP accumulation; developed as an immunotherapy and evaluated in combination with PD-L1 blockade and chemotherapy.
Novel regulator-of-anti-PD1 antibody program (preclinical)
A preclinical antibody program targeting an undisclosed regulator of anti-PD1 response demonstrated to reverse resistance in syngeneic mouse models; lead humanized antibody licensed to a commercial partner for further development.
Anti-IL-17 neutralizing antibody program (preclinical)
Generation and characterization of neutralizing monoclonal antibodies against IL-17 family cytokines with in vivo proof-of-concept showing antitumor activity through modulation of the tumor microenvironment.
Services
Discovery of novel immune checkpoints and regulators of anti-PD1/PDL1 response using in vivo genetic screens and resistant syngeneic mouse models; delivered via research partnerships and collaborations.
Generation, humanization and in vivo characterization of blocking and neutralizing monoclonal antibodies against immuno-oncology targets; support for partner-led preclinical programs.
Negotiation and execution of exclusive license agreements and collaborative development partnerships to advance discovery-stage antibody programs into clinical development.
Discovery of novel immune checkpoints and regulators of anti-PD1/PDL1 response using in vivo genetic screens and resistant syngeneic mouse models; delivered via research partnerships and collaborations.
Generation, humanization and in vivo characterization of blocking and neutralizing monoclonal antibodies against immuno-oncology targets; support for partner-led preclinical programs.
Negotiation and execution of exclusive license agreements and collaborative development partnerships to advance discovery-stage antibody programs into clinical development.
Expertise Areas
- Immuno-oncology target discovery
- Monoclonal antibody discovery and engineering
- Preclinical efficacy and validation in syngeneic models
- Translational research and biomarker development
Key Technologies
- Monoclonal antibody humanization
- In vivo genetic knockout screening
- Syngeneic mouse tumor models
- Mass cytometry (CyTOF) / single-cell profiling
News & Updates
Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming CICON24 meeting to be held at the Gaylord National Resort & Convention Center in National Harbor, MD (Washington, DC area) September 8-11, 2024.
OREGA Biotech announced that the first patient was dosed in the Phase 2 MATISSE trial evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 monoclonal antibody, in early-stage non-small cell lung cancer.
Professor Armand Bensussan was awarded the Galien Prize 2020 for his research on the development of lacutamab, a monoclonal antibody targeting KIR3DL2 for T cell lymphomas.
Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming CICON24 meeting to be held at the Gaylord National Resort & Convention Center in National Harbor, MD (Washington, DC area) September 8-11, 2024.
OREGA Biotech announced that the first patient was dosed in the Phase 2 MATISSE trial evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 monoclonal antibody, in early-stage non-small cell lung cancer.
Professor Armand Bensussan was awarded the Galien Prize 2020 for his research on the development of lacutamab, a monoclonal antibody targeting KIR3DL2 for T cell lymphomas.